LXRX - Lexicon Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place
The Woodlands, TX 77381
United States
281-863-3000
http://www.lexpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees202

Key Executives

NameTitlePayExercisedYear Born
Mr. Lonnel CoatsPres, CEO & Director1.05MN/A1965
Mr. Jeffrey L. WadeExec. VP of Corp. & Admin. Affairs and CFO606.99kN/A1965
Dr. Pablo LapuertaExec. VP & Chief Medical Officer534.96kN/A1963
Dr. Praveen TyleExec. VP of R&D637.46kN/A1960
Mr. Alexander A. SantiniExec. VP & Chief Commercial Officer514.05kN/A1959
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Corporate Governance

Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.